Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22577669 | 1.00 | KMT2A (0.50) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL21436136 | 0.98 | KMT2A (0.49) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL20305531 | 0.98 | KMT2A (0.49) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL20129063 | 0.98 | KMT2A (0.51) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL20128999 | 0.97 | KMT2A (0.49) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL20120347 | 0.95 | KMT2A (0.48) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL20214007 | 0.95 | KMT2A (0.48) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL18364935 | 0.95 | KMT2A (0.54) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL7057539 | 0.95 | KMT2A (0.54) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL2913896 | 0.95 | KMT2A (0.54) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | ASTRAZENECA PHARMACEUTICALS LP | 2019-06-27 | — | — | US | disclosed |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | ASTRAZENECA PHARMACEUTICALS LP | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | F12, CCNY, CCNE1 | KMT2A 2404/4885MEN1 474/4885KDM4C 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.